AgeX Therapeutics
Open
$2.09
Prev. Close
$2.09
High
$2.10
Low
$2.08
Market Snapshot
$25.12M
-1.2
-4.88
$56K
16
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 16 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 16 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Recently from Cashu
AgeX Therapeutics Gains Insights from Chemistry's Award-Winning Advertising and Community Engagement Strategies
### Chemistry's Creative Leadership in Advertising AgeX Therapeutics, at the forefront of biotechnology and regenerative medicine, may find inspiration in the recent achievements of Chemistry, an inde…
Chemistry Agency Recognized for Creativity and Community Engagement Under Taylor Guglielmo's Leadership
Chemistry Agency Achieves Recognition for Innovative Leadership and Community Engagement Chemistry, a distinguished independent creative advertising agency, demonstrates its commitment to excellence t…
SmartCustomer Launches Anti-Fraud Initiative to Enhance Trust in Online Shopping
Transforming Online Shopping: SmartCustomer's New Initiative Against Fraud SmartCustomer, previously known as Sitejabber, is making waves in the realm of online shopping with its recent rebranding and…
SmartCustomer Enhances Online Review Trust with New Verification Measures and AI Tools
Innovative Measures in Online Review Verification: SmartCustomer's New Approach SmartCustomer, previously known as Sitejabber, takes a significant step forward in enhancing trust in online shopping th…